Opus Genetics (IRD) announced that the first participant has been dosed in the Company’s OPGx-BEST1 Phase 1/2 clinical trial for Best disease. Best disease, or vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by mutations in the BEST1 gene, leading to progressive vision loss and, in some cases, blindness. OPGx-BEST1 is an emerging gene therapy administered through a one-time subretinal injection designed to restore function to the retinal pigment epithelium cells affected by mutations in the BEST1 gene.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Promising Advancements in Opus Genetics’ Retinal Disease Platform Support Buy Rating
- Opus Genetics: Buy Rating Backed by Strong Financials, Regulatory Support, and Promising Study Progress
- Opus Genetics reports Q3 EPS (25c) vs (29c) last year
- Opus Genetics Announces $23M Direct Offering
- Positive Outlook for Opus Genetics: Regulatory Support and Financial Stability Justify Buy Rating